Oral contraceptives and cancers of the breast and of the female genital tract. Interim results from a case-control study
Open Access
- 1 August 1986
- journal article
- research article
- Published by Springer Nature in British Journal of Cancer
- Vol. 54 (2) , 311-317
- https://doi.org/10.1038/bjc.1986.178
Abstract
We analysed data from a case-control investigation conducted in Milan, Northern Italy, to evaluate the relation between the use of combination oral contraceptives and the risk of cancers of the breast, ovary, endometrium and cervix uteri. For the present analysis, 776 cases of histologically confirmed breast cancer, 406 of epithelial ovarian cancer and 170 of endometrial cancer aged under 60 were compared with a group of 1,282 subjects below age 60 admitted for a spectrum of acute conditions apparently unrelated to oral contraceptive use or to any of the known or potential risk factors for the diseases under study. Likewise, 225 cases of invasive cervical cancer were compared with 225 age-matched inpatient controls, and 202 cases of cervical intra-epithelial neoplasia with 202 outpatient controls identified in the same screening clinics. The age-adjusted relative risk estimates for ever vs. never use of combination oral contraceptives were 1.04 (95% confidence interval (CI) 0.73-1.37) for breast cancer, 0.68 (95% CI = 0.48-0.97) for epithelial ovarian cancer, 0.50 (95% CI = 0.23-1.12) for endometrial cancer, 1.49 (95% CI = 0.88-2.55) for cervical cancer and 0.77 (95% CI = 0.50-1.18) for cervical intra-epithelial neoplasia. The risk of ovarian cancer decreased and that of invasive cervical cancer increased with longer duration of use. Neither duration of oral contraceptive use nor time since first or last use significantly altered a user's risk of other neoplasms considered. Likewise, analysis of sub-groups of age, parity or other potentially important covariates did not show any important interaction, and allowance for them by means of logistic regression did not materially modify any of the results. These data confirm that combination oral contraceptives confer some protection against ovarian and endometrial cancers but may increase the risk of invasive cervical cancer if used for several years, and indicate that the past or current pattern of oral contraceptive use in Italy is unlikely materially to affect the risk of breast cancer.Keywords
This publication has 21 references indexed in Scilit:
- ORAL CONTRACEPTIVES AND BREAST CANCER IN YOUNG WOMENThe Lancet, 1985
- "PAP" SMEAR AND THE RISK OF CERVICAL NEOPLASIA: QUANTITATIVE ESTIMATES FROM A CASE-CONTROL STUDYThe Lancet, 1984
- ORAL CONTRACEPTIVES AND BREAST CANCERThe Lancet, 1983
- BREAST CANCER IN YOUNG WOMEN AND USE OF ORAL CONTRACEPTIVES: POSSIBLE MODIFYING EFFECT OF FORMULATION AND AGE AT USEThe Lancet, 1983
- Breast cancer and oral contraceptive use: A case-control studyJournal of Chronic Diseases, 1983
- Oral Contraceptives and Breast CancerInternational Journal of Epidemiology, 1982
- Incidence of ovarian cancer in relation to the use of oral contraceptivesInternational Journal of Cancer, 1981
- Decreased Risk of Endometrial Cancer among Oral-Contraceptive UsersNew England Journal of Medicine, 1980
- A case control study of carcinoma of the ovary.Journal of Epidemiology and Community Health, 1977
- A CASE CONTROL STUDY INTO THE POSSIBLE EFFECTS OF BIRTH CONTROL PILLS ON PRE‐CLINICAL CARCINOMA OF THE CERVIXBJOG: An International Journal of Obstetrics and Gynaecology, 1972